Second quarter sales grew 5% year-over-year to $3 billion, with broad-based segment growth and strong performance in Advanced Surgery and drug compounding. Adjusted EPS was $0.56, aided by a one-time $75 million tariff refund. Full-year guidance was raised for both sales and EPS, with continued foc…
Second quarter sales grew 5% year-over-year to $3 billion, with broad-based segment growth and strong performance in Advanced Surgery and drug compounding. Adjusted EPS was $0.56, aided by a one-time $75 million tariff refund. Full-year guidance was raised for both sales and EPS, with continued focus on operational execution and deleveraging.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
